|
Daily Medical Update
Neuropathic Pain (Gabapentinoids, SNRIs, topicals)
Friday, March 13, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Cochrane Database Syst Rev (2026) - Systematic Review/Meta-analysis
Key Findings
- Across 21 randomized trials (n=2,187), cannabis-based medicines showed no clear improvement in achieving ≥50% pain relief versus placebo.
- THC/CBD products increased nervous-system adverse events and treatment discontinuation despite only small gains in global-improvement ratings.
📋 Practice Implication: Keep cannabinoids off routine first-line neuropathic pain pathways and reserve use for refractory cases after standard options fail.
|
Expert Opin Pharmacother (2026) - Randomized Comparative Trial
Key Findings
- Mirogabalin plus opioids produced greater 4-week pain reduction than opioids alone (between-group LS mean NRS difference -1.5; p=0.0017).
- Responder rates (≥30% pain reduction) were higher with combination therapy (72.3% vs 42.0%), with more somnolence and dizziness.
📋 Practice Implication: For persistent neuropathic features on opioid therapy, add a gabapentinoid deliberately and build early sedation/fall monitoring into follow-up.
|
3. Effects of benfotiamine treatment over 12 months in symptomatic diabetic polyneuropathy (BOND study).
BMJ Open Diabetes Res Care (2026) - Randomized Placebo-Controlled Trial
Key Findings
- Twelve months of benfotiamine did not improve the primary nerve-regeneration endpoint (corneal nerve fiber length) versus placebo.
- Compared with placebo, benfotiamine did not improve nerve-conduction, sensory testing, or symptom-scale outcomes over 12 months.
📋 Practice Implication: Deprescribe benfotiamine when used solely for diabetic neuropathy disease modification and redirect effort to therapies with demonstrated benefit.
|
4. Efficacy of non-pharmacological interventions for chemotherapy-induced peripheral neuropathy: network meta-analysis.
Support Care Cancer (2026) - Systematic Review/Network Meta-analysis
Key Findings
- In 27 RCTs (n=2,136), exercise interventions improved neurotoxicity scores compared with medication-based controls.
- Acupuncture reduced neuropathic pain symptom scores and lowered CIPN incidence across pooled comparisons.
📋 Practice Implication: Standardize referral pathways for exercise and acupuncture in chemotherapy-induced neuropathy rather than escalating medications alone.
|
5. Acupuncture for paclitaxel-induced peripheral neuropathy in early breast cancer (PACLILIN).
Support Care Cancer (2026) - Randomized Sham-Controlled Trial
Key Findings
- True acupuncture improved neuropathic symptom subscales and lowered pain VAS at week 8 versus sham treatment.
- By week 12, between-group differences faded, indicating a short-duration analgesic effect without maintenance sessions.
📋 Practice Implication: Use time-limited acupuncture blocks for symptom flares in CIPN and reassess at 6-8 weeks before extending treatment.
|
6. Exercise training and balance function in diabetic peripheral neuropathy: GRADE meta-analysis.
Front Public Health (2026) - Systematic Review/Meta-analysis
Key Findings
- Across 16 RCTs (n=759), exercise improved Berg Balance Scale and Timed Up and Go outcomes versus control care.
- One-leg-stand performance improved with training, while six-minute walk distance showed no significant pooled effect.
📋 Practice Implication: Prioritize supervised balance-focused exercise as foundational management for diabetic neuropathy with instability or falls risk.
|
7. Global herpes zoster burden in adults with COPD: systematic review and meta-analysis.
Eur Respir Rev (2026) - Systematic Review/Meta-analysis
Key Findings
- Adults with COPD had higher herpes zoster incidence, and post-herpetic neuralgia occurred more often than in non-COPD comparators (rate ratio 1.50).
- COPD patients on corticosteroids had higher zoster risk than other COPD groups, with a corresponding increase in post-herpetic neuralgia burden.
📋 Practice Implication: Trigger standing shingles-vaccine outreach in COPD panels, especially for patients exposed to systemic corticosteroids.
|
|
Recent high-level evidence in neuropathic pain emphasizes selective use of gabapentinoids and stronger integration of nonpharmacologic care. Large trials and meta-analyses show several commonly used adjuncts provide limited meaningful benefit, while targeted add-on strategies and structured exercise-based programs can improve pain-related function in defined populations. For primary care, the key shift is toward indication-specific prescribing, deprescribing low-value options, and proactive prevention of high-risk neuropathic syndromes.
|
|